Transcutaneous electrical nerve stimulation using novel unbalanced biphasic waveform and novel electrode arrangement

Information

  • Patent Grant
  • 11511106
  • Patent Number
    11,511,106
  • Date Filed
    Tuesday, December 15, 2020
    3 years ago
  • Date Issued
    Tuesday, November 29, 2022
    a year ago
Abstract
The present invention is directed to transcutaneous electrical nerve stimulation (TENS) devices which utilize novel stimulation waveforms and novel arrangements of TENS electrodes to improve the efficiency of power consumption while enhancing therapeutic effects.
Description
FIELD OF THE INVENTION

This invention relates generally to Transcutaneous Electrical Nerve Stimulation (TENS) devices that deliver electrical current across the intact skin of a user via electrodes so as to provide symptomatic relief of chronic pain and other therapeutic benefits. More particularly, this invention discloses the construction of novel TENS stimulation waveforms and novel arrangements of TENS electrodes which improve the efficiency of power consumption while enhancing therapeutic effects.


BACKGROUND OF THE INVENTION

Transcutaneous electrical nerve stimulation (TENS) is the delivery of electricity across the intact surface of the skin to activate underlying nerves; generally with the objective of pain relief. An electrical circuit generates stimulation pulses with specified characteristics. One or more pairs of electrodes, placed on the user's skin, transduce the electrical pulses and thereby stimulate underlying nerves in order to trigger an analgesic response.


Pain relief from TENS stimulation often begins within 15 minutes of the stimulation onset and may last up to an hour following the completion of the stimulation period (also known as a “therapy session”). For optimal pain relief, each therapy session should run for at least 30 minutes and preferably 60 minutes. To maintain pain relief (i.e., analgesia), TENS therapy sessions typically need to be initiated at regular intervals, such as every other hour. Newly developed wearable TENS devices such as the QUELL® device by Neurometrix, Inc. of Waltham, Mass., USA provide users with an option to automatically restart therapy sessions at pre-determined time intervals.


Battery life is an engineering challenge in portable devices. The waveform of the stimulation pulse has a significant impact on the battery life of a TENS device. Symmetric biphasic rectangular pulses are often used in TENS devices but such pulse waveforms may not be optimal for maximizing battery life.


The present invention is directed to TENS devices which utilize novel stimulation waveforms and novel arrangements of TENS electrodes to improve the efficiency of power consumption while enhancing therapeutic effects.


SUMMARY OF THE INVENTION

The present invention is directed to transcutaneous electrical nerve stimulation (TENS) devices which utilize novel stimulation waveforms and novel arrangements of electrodes to improve the efficiency of power consumption while enhancing therapeutic effects.


In one preferred form of the present invention, there is provided apparatus for providing transcutaneous electrical nerve stimulation to a user, said apparatus comprising:


a housing;


a stimulation unit for electrically stimulating nerves using asymmetric biphasic electrical pulses, wherein during each phase of an asymmetric biphasic electrical pulse, said stimulation unit generates a voltage at an anode that is higher than a voltage at a cathode so as to allow current to flow from the anode to the cathode, and wherein said stimulation unit delivers a larger amount of electrical charge in the second phase of the asymmetric biphasic electrical pulse than the amount of electrical charge delivered in the first phase of the asymmetric biphasic electrical pulse using the same anode voltage setting in both phases of the asymmetric biphasic electrical pulse by taking advantage of the electrical charge accumulated during the first phase of the asymmetric biphasic electrical pulse;


a control unit for controlling the electrical stimulation delivered by said stimulation unit; and


an electrode array connectable to said stimulation unit, said electrode array comprising a substrate and at least first and second electrodes, the at least first and second electrodes being mounted to said substrate with a predetermined arrangement, such that when said substrate is placed on the user, said first electrode overlays a first nerve but not a second nerve and said second electrode overlays the second nerve but not the first nerve.


In another preferred form of the present invention, there is provided apparatus for providing transcutaneous electrical nerve stimulation to a user, said apparatus comprising:


a housing;


a stimulation unit for electrically stimulating nerves using asymmetric biphasic electrical pulses, wherein said stimulation unit delivers a larger amount of electrical charge in the second phase of the asymmetric biphasic electrical pulse than the amount of electrical charge delivered in the first phase of the asymmetric biphasic electrical pulse using the same voltage output level by taking advantage of the electrical charge accumulated during the first phase of the asymmetric biphasic electrical pulse;


a control unit for controlling the stimulation delivered by said stimulation unit; and


an electrode array connectable to said stimulation unit, said electrode array comprising a substrate and at least first and second electrodes, the at least first and second electrodes being mounted to said substrate with a predetermined arrangement, such that when said substrate is placed on the user, said first electrode overlays a first nerve but not a second nerve and said second electrode overlays the second nerve but not the first nerve.


In another preferred form of the present invention, there is provided a method for providing transcutaneous electrical nerve stimulation therapy to a user, said method comprising:


providing a stimulation unit for generating asymmetric biphasic electrical pulses, wherein the asymmetric biphasic electrical pulses are generated by creating a voltage difference between an anode voltage and a cathode voltage, and the amount of electrical charge delivered in the second phase of an asymmetric biphasic electrical pulse is larger than the amount of electrical charge delivered in the first phase of the asymmetric biphasic electrical pulse using the same anode voltage during the first and second phases of the asymmetric biphasic electrical pulse by taking advantage of the electrical charge accumulated during the first phase of the asymmetric biphasic electrical pulse;


providing an electrode array connectable to said stimulation unit, said electrode array comprising a substrate and at least first and second electrodes, the at least first and second electrodes being mounted to said substrate with a predetermined arrangement, such that when said substrate is placed on the user, said first electrode overlays a first nerve but not a second nerve and said second electrode overlays the second nerve but not the first nerve; and


using said stimulation unit and said electrode array to apply asymmetric biphasic electrical pulses to the skin of a user.


In another preferred form of the present invention, there is provided a method for providing transcutaneous electrical nerve stimulation to a user, the method comprising:


providing a stimulation unit for generating asymmetric biphasic electrical pulses, wherein said stimulation unit delivers a larger amount of electrical charge in the second phase of the asymmetric biphasic electrical pulse than the amount of electrical charge delivered in the first phase of the asymmetric biphasic electrical pulse without increasing the voltage output of said stimulator unit by taking advantage of the electrical charge accumulated during the first phase of the asymmetric biphasic electrical pulse, and providing an electrode array connectable to said stimulation unit, said electrode array comprising at least first and second electrodes;


placing the electrode array on the user so that the first electrode overlays a first nerve but not a second nerve and the second electrode overlays the second nerve but not the first nerve; and


using said stimulation unit to apply asymmetric biphasic electrical pulses to the skin of the user.


In another preferred form of the present invention, there is provided apparatus for providing transcutaneous electrical muscle stimulation to a user, said apparatus comprising:


a housing;


a stimulation unit for electrically stimulating muscles using an asymmetric biphasic electrical pulse, wherein during each phase of an asymmetric biphasic electrical pulse, said stimulation unit generates a voltage at an anode that is higher than a voltage at a cathode so as to allow current to flow from the anode to the cathode, and said stimulation unit delivers a larger amount of electrical charge in the second phase of the asymmetric biphasic electrical pulse than the amount of electrical charge delivered in the first phase of the asymmetric biphasic electrical pulse using the same anode voltage setting in both phases of the asymmetric biphasic electrical pulse by taking advantage of the electrical charge accumulated during the first phase of the asymmetric biphasic electrical pulse;


a control unit for controlling the stimulation delivered by said stimulation unit; and


an electrode array connectable to said stimulation unit, said electrode array comprising a substrate and at least first and second electrodes, the at least first and second electrodes being mounted to said substrate with a predetermined arrangement, such that when said substrate is placed on the user, said first electrode overlays a first muscle but not a second muscle and said second electrode overlays the second muscle but not the first muscle.


In another preferred form of the present invention, there is provided a method for providing transcutaneous electrical muscle stimulation therapy to a user, said method comprising of the steps of:


placing an electrode array on the skin of a user so that a first electrode of said electrode array overlays a first muscle but not a second muscle and so that a second electrode of said electrode array overlays the second muscle but not the first muscle;


controlling a stimulator unit to generate asymmetric biphasic electrical pulses; and


delivering said asymmetric biphasic electrical pulses to the electrode array, wherein the second phase of the asymmetric biphasic electrical pulses delivers a larger amount of electrical charge than the first phase of the asymmetric biphasic electrical pulses without the need to increase the output voltage of the stimulator unit during the second phase of the asymmetric biphasic electrical pulses by taking advantage of the electrical charge accumulated during the first phase of the asymmetric biphasic electrical pulse.





BRIEF DESCRIPTION OF THE DRAWINGS

These and other objects and features of the present invention will be more fully disclosed or rendered obvious by the following detailed description of the preferred embodiments of the invention, which is to be considered together with the accompanying drawings wherein like numbers refer to like parts, and further wherein:



FIG. 1 is a schematic view of a traditional TENS stimulator using monophasic stimulation pulses to stimulate a nerve via a conventional electrode arrangement;



FIG. 2 is a schematic view of a traditional TENS stimulator using biphasic stimulation pulses to stimulate a nerve via the conventional electrode arrangement shown in FIG. 1;



FIG. 3 is a schematic view of a novel TENS stimulator formed in accordance with the present invention;



FIG. 4 is a schematic view of novel arrangements of TENS electrodes placed on the lower leg of a user for delivering asymmetric biphasic stimulation pulses regulated by the novel TENS stimulator shown in FIG. 3;



FIG. 5 is a schematic view of an asymmetric biphasic stimulation current pulse and associated voltage profile on the current source of the novel TENS stimulator shown in FIG. 3 when the biphasic stimulation current pulse is applied to a human body as modeled by a resistor-capacitor network;



FIG. 6 is a schematic view of targeted and actual biphasic stimulation current pulse and associated voltage profile of the novel TENS stimulator shown in FIG. 3 when the voltage falls below the target value to cause actual stimulation current pulse profile to be different from the target profile; and



FIG. 7 is a schematic flowchart showing exemplary operation of the novel TENS stimulator shown in FIG. 3 to regulate the high voltage circuit output for increasing battery efficiency.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
TENS in General

Transcutaneous electrical nerve stimulation, typically abbreviated as TENS, is the delivery of electricity across the intact surface of the skin so as to activate underlying nerves, generally with the objective of pain relief. A conceptual model for how peripheral nerve stimulation leads to pain relief was proposed by Melzack and Wall in 1965 (Melzack R, Wall P D. Pain mechanisms: a new theory. Science. Nov. 19, 1965; 150(699):971-979). Their theory suggests that the activation of sensory nerves (Aβ fibers) closes a “pain gate” in the spinal cord which inhibits the transmission of pain signals carried by nociceptive afferents (C and Aδ fibers) to the brain. In the past 20 years, the anatomic pathways and molecular mechanisms that may underlie the pain gate have been elucidated. Sensory nerve stimulation activates the descending pain inhibition system, primarily the periaqueductal gray (PAG) and rostroventral medial medulla (RVM) located in the midbrain and medulla sections of the brainstem, respectively (DeSantana J M, Walsh D M, Vance C, Rakel B A, Sluka K A. Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain. Curr Rheumatol Rep. December 2008; 10(6):492-499). The PAG has neural projections to the RVM, which in turn has diffuse bilateral projections into the spinal cord dorsal horn (Ossipov M H, Dussor G O, Porreca F. Central modulation of pain. J Clin Invest. November 2010; 120(11):3779-3787). Peripheral nerve stimulation activates the PAG, which triggers the RVM to broadly inhibit pain signal transmission in the spinal cord dorsal horn. Although it is activated by localized peripheral nerve stimulation, the descending pain inhibition system has analgesic effects that may extend beyond the stimulation site to provide broad pain relief (Dailey D L, Rakel B A, Vance C G, et al. Transcutaneous electrical nerve stimulation reduces pain, fatigue and hyperalgesia while restoring central inhibition in primary fibromyalgia. Pain. November 2013; 154(11):2554-2562).


As described above, TENS induces analgesia by stimulating peripheral nerves. A peripheral nerve is defined as a nerve, which is a collection of nerve fibers (i.e., axons), that is outside of the brain and spinal cord. Peripheral nerves may comprise nerve fibers that provide sensory, motor or autonomic functions. TENS is primarily intended to stimulate somatic peripheral nerves, meaning nerve fibers that either bring sensory information into the nervous system or carry motor control information to the muscles. As peripheral nerves descend from the spinal cord they may break off into various branches. Some of these branches may be large enough that they are named peripheral nerves. For example, the sciatic nerve, which is formed from spinal nerves in the lumbosacral region, travels all the way from the lower back to the knee as one major nerve. In the popliteal fossa (i.e., behind the knee) it branches into the tibial nerve and the common peroneal nerve. These two nerves then branch into additional nerves further down the leg and into the foot. Most peripheral nerve branches are smaller and provide limited function such as innervating a muscle or providing sensation to a particular area of skin. In the latter case, the branch may be described as a cutaneous branch. In some cases, small branches of peripheral nerves are called collaterals.


TENS is characterized by a number of stimulation parameters including the stimulation pulse shape, amplitude, duration, pattern, and frequency. Increasing pulse amplitude or duration, or both, increases the pulse intensity (intensity=amplitude*duration) of the TENS therapy. For the same intensity, the relative effectiveness of the stimulation pulse decreases with longer duration due to the strength-duration relation of a nerve. Stimulation at an intensity below the level of sensory perception does not provide pain relief, and the degree of analgesia is correlated to the stimulation intensity. Scientific studies and clinical experience suggest that therapeutically effective TENS occurs at an intensity that feels “strong but comfortable” to the user.


Looking now at FIG. 1, the dose of the TENS therapy is approximately defined as CE*f*Δ. Quantity CE 223 is the effective charge per pulse, or the portion of total pulse charge that is actually effective in stimulating nerve fibers with the resulting nerve pulses traveling proximally to the central nervous system. Quantity f is the pulse frequency, and its inverse is the pulse period T 224. Quantity Δ 242 is the therapy session duration. Pulse frequency f is limited by the frequency response of the nerve, which is determined by the temporal excitability profile of the nerve including its refractory period, and the frequency response of the central neural circuits associated with analgesia. In general, analgesic efficacy drops off over about 100 Hz. Therapy session duration Δ 242 is limited by patient preferences and by the physiology of the endogenous opioid system, where opioid concentration starts to drop after about 1 hour of stimulation.


To stimulate a peripheral nerve 205, a TENS stimulator 201 needs at least two separate contact areas with the skin (e.g., cathode electrode 210 and anode electrode 215) so that a closed circuit can be formed. Hydrogel-based electrodes (e.g., cathode electrode 210 and anode electrode 215) are preferably used to create the electrical interface between the TENS stimulator and the skin in the contact areas. Important parameters for electrical pulses are amplitude IC 221 and duration DC 222. For each monophasic pulse 235, its intensity or total pulse charge INC is defined as the product of IC and DC: INC=IC*DC. The nerve segment under cathode electrode 210 is activated by an electrical pulse when the intensity INC exceeds a threshold. The exact threshold value depends upon many factors, including the user's age, height and weight, biophysical characteristics of the nerve being stimulated, and electrode geometry. In general, the stimulation current amplitude IC 221 must also be above a minimum value called the rheobase to activate the nerve segment under the electrode. For a sequence of monophasic pulses 220, each pulse with the total pulse charge INC contributes effectively to the activation of the nerve impulse 216 that travels proximally along the nerve. Therefore, the effective charge CE 223 equals the total pulse charge: CE=INC=IC*DC in the case of monophasic pulse TENS.


Although monopolar stimulation pulses 220 are efficient in that the effective charge is equal to the pulse charge, monopolar stimulation pulses are not generally used in TENS stimulation due to known adverse skin reactions under anode 215 and cathode 210 following a prolonged period of stimulation. More particularly, during stimulation, negatively charged ions in the skin will be attracted towards the anode electrode and their excessive accumulation will cause an acid reaction in the skin area under the anode 215. Similarly, positively charged ions in the skin will move to the cathode electrode and their excessive concentration will cause an alkaline reaction in the skin area under the cathode 210. To overcome these adverse skin reactions, biphasic stimulation pulses are typically used in modern TENS devices.


Looking now at FIG. 2, the biphasic pulses 230 typically used in modern TENS devices (e.g., TENS stimulator 201) have a second phase 236 following the first phase 235 for each stimulation pulse. The second phase 236 of the biphasic pulse serves a primary purpose of balancing the charge delivered during the first phase 235 of the biphasic pulse, thereby preventing adverse skin reactions due to the build-up of charged ions under the electrodes. Electrically, the second phase 236 of the biphasic pulse reverses the roles of the anode and cathode, but no effective nerve stimulation should be expected under the “new” cathode (i.e., electrode 215) with the electrode arrangement shown in 245. There are two reasons for this. First, the nerve segment under electrode 215 is hyperpolarized during the first phase 235 of the biphasic pulse, making it more difficult to be activated by the stimulation current IA 237 in the second phase 236 of the biphasic pulse. Second, even if the nerve segment under electrode 215 could be activated by the second phase 236 of the biphasic stimulation pulse, any resulting nerve pulses 217 could not travel proximally (i.e., towards the central nervous system) past electrode 210 because of the refractory period of the nerve segment located under electrode 210. More particularly, the refractory period refers to the inability of a nerve fiber to transmit a second pulse within a certain time period of the first pulse passing through the nerve segment. The refractory period for a human peripheral nerve is generally on the order of several milliseconds, while the delay between the two phases of a TENS biphasic pulse is usually less than one-tenth of a millisecond. Hence, the second phase 236 of the biphasic pulse is delivered to electrode 215 and activates a nerve pulse 217 originating from the nerve segment under electrode 215. Because the nerve segment under electrode 210 is still in its refractory period due to nerve pulse activation earlier from the first phase 235 of the biphasic pulse, the nerve pulse 217 is prevented from traveling through the nerve segment under the electrode 210 in the proximal direction. As a result, the second phase 236 of the biphasic pulse does not provide the beneficial effect of activating any nerve pulse that can travel proximally to contribute to pain relief. In this case, the effective charge is still CE=IC*DC, even though the biphasic pulses have a total pulse charge of (IC*DC+IA*DA), i.e., the pulse charge IC*DC of the first phase of the biphasic pulse plus the pulse charge IA*DA of the second phase of the biphasic pulse. In other words, the effective charge CE 233 of the biphasic pulse is essentially just the pulse charge of the first phase of the biphasic pulse, and the second phase of the biphasic pulse does not produce effective nerve stimulation. However, as noted above, the use of biphasic pulses is nonetheless beneficial to overcome adverse skin reactions under the electrodes, and hence has often been adopted with TENS devices.



FIG. 3 provides a functional block diagram for a novel TENS stimulator 300 when connected to a patient load 350. Novel TENS stimulator 300 is configured to provide biphasic pulses in accordance with the present invention, however, for clarity of illustration, FIG. 3 shows only the first phase of a biphasic pulse generated by novel TENS stimulator 300 (and omits the second phase of the biphasic pulse). Switch 308 can be open when the TENS stimulator is not delivering current to the patient load. The load to the TENS stimulator output terminals (i.e., anode terminal 302 and cathode terminal 303) consists of the electrodes, body tissue, and the interface between the electrodes and skin (note that, even though TENS stimulator 300 is configured to deliver biphasic pulses, terminal 302 is referred to as the “anode” terminal, and terminal 303 is referred to as the “cathode” terminal, since they typically serve this function during the first phase of the biphasic pulse). A common and effective circuit model of the skin-electrode contact and tissue volumetric impedance (i.e., the load to the stimulator) is a resistor in series with a parallel resistor-capacitor (RC) circuit as shown inside 350. When switch 308 is closed, anode terminal voltage VA at the anode terminal 302 is the same as the high voltage circuit voltage VP at the high voltage circuit output 309. In order to deliver an electrical stimulation pulse 320 with a target current amplitude I 321 for a duration D 322, a minimum voltage bias VCSmin must be maintained at the current source 306. The voltage VAC=VA−VC between anode terminal 302 (i.e., the anode electrode connector) and cathode terminal 303 (i.e., the cathode electrode connector), as a result of a stimulation current pulse with amplitude I 321, is given by







τ
*


d


V

A

C



dt


=


-

V

A

C



+

I
*

(


R
S

+

R
P


)








where the time constant τ=RP*CP, i.e., a product of capacitor value CP of a capacitive component 351 and resistor value RP of a resistive component 353. Resistor value RS is for a resistive component 352 of the patient load. The above equation has the solution

VAC(t)=I*[RS+RP*(1−e−t/τ)], 0≤t≤D


Using RS=200Ω, RP=130 kΩ, CP=0.1 μF (an equivalent circuit model of a healthy subject electrode-skin interface) gives τ=13 milliseconds. Stimulation current pulse duration D 322 has a typical range of 100-200 microseconds, so we have D<<τ. Given that t<D<<τ, VAC(t) can be approximated by

VAC(t)≈I*[RS+t/CP], 0≤t≤D  Eq. (1)

To maintain proper operation of the TENS stimulator for delivering a current pulse of amplitude I and duration D, the high voltage VP must be set high enough to ensure VCS is at least VCSmin. The required anode voltage VA reaches its maximum value VAmax at time D, and the maximum value is approximately







V
A

ma





x


=




V

A

C




(
D
)


+

I
*

R
I


+

V

C

S


m





i





n



=


I
*

(


R
S

+

R
I


)


+

V

C

S


m





i





n


+


(

I

C
P


)

*
D








where RI 355 is a sensing resistor with a known value internal to the TENS stimulator for measuring the actual current delivered to the stimulator load 350. In a preferred embodiment of the present invention, the voltage VI across the sensing resistor RI is measured via an analog-to-digital converter ADC 311 and the microprocessor μPC 312 then calculates the actual current delivered to the load 350 by dividing the voltage value VI by the resistance value of RI. In a preferred embodiment of the present invention, the value of RI is set to 10Ω. Therefore, the target output voltage VP must be set minimally at the value VAmax in order for the TENS stimulator to deliver current pulses with the required amplitude and duration. In a preferred embodiment, VAC(D) is not directly measured. Rather, the voltage VC is measured by the measurement circuit MMC 314 at time t=D or at a slightly earlier time. High voltage circuit output VP is adjusted through microprocessor μPC 312 so that voltage VC is as close as possible to zero at the end of the stimulation pulse duration D while maintaining the current amplitude during the pulse duration D.


The setting of the high voltage VP directly affects battery life. Nominal voltage of a battery VB 305 is about 4.2 volts. A high-voltage generating circuit 310 is used to step-up the battery nominal voltage to the required high voltage VP. Power conservation principles dictate the following relationship between battery current draw IB 301 and high voltage VP at 309:

β*IB*VB=I*VP*D/T

where β (<100%) is the high-voltage circuit efficiency. For a battery of a given capacity QB, the time TB for the battery capacity to deplete is given by







T
B

=


β
*

Q
B

*
T
*

V
B



I
*
D
*

V
P








The actual battery life is shorter than, but proportional to, this theoretical upper bound. It will, therefore, be appreciated that battery life can be improved if the high voltage VP can be maintained at the minimum value that is required to deliver a desired stimulation pulse of amplitude I and duration D.


Maximizing Battery Life Through the Use of Novel Biphasic Waveform with Asymmetric Phase Morphology and Novel Arrangement of TENS Electrodes

The novel TENS stimulator of the present invention is designed to maximize battery life (i.e., maximize TB) while maintaining the TENS therapeutic effectiveness. More particularly, the novel TENS stimulator of the present invention utilizes biphasic stimulation pulses (instead of monophasic pulses). The addition of a second phase with reversed polarity minimizes skin irritation due to acid or alkaline reactions. In accordance with the present invention, a novel asymmetric biphasic stimulation pulse morphology is used which leverages the “voltage multiplier effect” (see below) to maximize the stimulation intensity effect of both phases of the pulse without increasing high voltage settings. Significantly, a novel electrode placement scheme allows both positive and negative phases of each biphasic stimulation pulse to effectively activate peripheral nerves for pain relief.


In this application, the word “asymmetric” is used to describe differences in the electrical current profiles of the two phases of a biphasic stimulation pulse. In addition, the word “asymmetric” is used to describe differences in the geometric areas of the two phases of a biphasic stimulation pulse. The area of an electrical stimulation pulse corresponds to the total charge delivered. Therefore, an asymmetric biphasic stimulation pulse may deliver unequal charges in each of the two phases of the biphasic stimulation pulse, causing the total charge delivered in the asymmetric biphasic stimulation pulse to be unbalanced (i.e., causing the accumulation of a “net” positive charge or a “net” negative charge under an electrode at the end of the second phase of the biphasic stimulation pulse).


In a preferred embodiment of the present invention, two electrode pads are placed on the user's body in such a way that each electrode pad overlays a distinct set of nerve fibers. FIG. 4 provides an illustrative example. More particularly, an electrode array 405 with two electrodes (e.g., electrode A 402 and electrode B 404) is placed on the lower leg 410 of a user, with the two electrodes aligned approximately on the same cross-sectional plane 411. Preferably, electrode array 405 comprises a substrate having electrode A 402 and electrode B 404 mounted thereto with a predetermined configuration, wherein the substrate is configured to be held against the skin of the patient in a band-like matter. By way of example but not limitation, the TENS device may be configured as an adjustable band for mounting circumferentially around the limb of the user, with electrode array 405 being secured to the skin-facing side of the TENS device and captured against the skin of the patient. See, for example, U.S. Pat. No. 8,948,876, issued Feb. 3, 2015 to NeuroMetrix, Inc. and Shai N. Gozani et al. for APPARATUS AND METHOD FOR RELIEVING PAIN USING TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, which patent is hereby incorporated herein by reference. Because peripheral nerves in the lower leg region primarily traverse in the proximal-to-distal direction, each electrode 402, 404 will overlay a different nerve (e.g., electrode A 402 will overlay nerve X 412 and electrode B 404 will overlay nerve Y 414). In this context, the term “nerve” is used, without limitation, to refer to a collection of nerve fibers such as from a major peripheral nerve or a branch of a peripheral nerve. By forming electrode array 405 as a substrate with electrodes 402, 404 mounted thereto with a predetermined configuration, and by appropriately sizing electrode array 405 for the target anatomy, electrodes 402, 404 may be quickly and easily positioned to overlay the appropriate nerves (e.g., nerve X 412 and nerve Y 414) when electrode array 405 is secured to the remainder of the TENS device and the TENS device is mounted to the limb of the patient in a band-like manner. The two electrodes 402, 404 are electrically connected to the cathode and anode terminals 303, 302 of the TENS stimulator unit (FIG. 3).


During the stimulation pulse segment HA (i.e., the first phase of the first biphasic pulse), nerve X 412 under electrode A 402 is activated by electrical stimulation with intensity IN1A=IC*DC and the resulting nerve pulses 416 travel proximally to contribute to the effective dose for pain relief. During the stimulation pulse segment P1B (i.e., the second phase of the first biphasic pulse), nerve Y 414 under electrode B 404 is activated by electrical stimulation with intensity IN1B=IA*DA and the resulting nerve pulses 418 travel proximally to contribute to the effective dose for pain relief. Significantly, even though the temporal separation between stimulation pulse segment P1A and stimulation pulse segment P1B is typically 0.1 milliseconds or shorter (i.e., less than the refractory period of a peripheral nerve), nerves X and Y are activated only once (by either stimulation pulse segment P1A or stimulation pulse segment P1B) due to the non-overlapping nature of the nerves, and therefore nerve fibers, under the electrodes and the disposition of the electrodes relative to the nerves. Therefore, both nerves X 412 and Y 414 can be activated during the first biphasic pulse (i.e., nerve X can be activated during the first phase of the biphasic pulse and nerve Y can be activated during the second phase of the biphasic pulse) and contribute to the overall effective dose for pain relief. Because each phase of the biphasic pulse activates a separate nerve with resulting nerve pulses contributing to the effective dose for pain relief, the effective charge CE is the same as the total pulse charge of (IC*DC+IA*DA) of this biphasic pulse. Stated another way, by applying the biphasic stimulation pulse across two electrodes, wherein each electrode overlies a different nerve, one electrode can activate one nerve during the first phase of the biphasic pulse and the other electrode can activate a second nerve during the second phase of the biphasic pulse. Therefore, each phase of the biphasic pulse operates to provide therapeutic nerve stimulation to the user, and the effective charge CE is provided by both phases of the biphasic pulse. As a result, with the electrode arrangement shown in FIG. 4, the effective charge CE delivered to the user with a biphasic pulse is (IC*DC)+(IA*DA); by contrast, with the electrode arrangement shown in FIG. 2, the effective charge CE delivered to the user with a biphasic pulse is (IC*DC).


The next biphasic stimulation pulse (i.e., stimulation pulse segment P2B and stimulation pulse segment P2A) occurs at approximately 125 milliseconds (80 Hertz) after the first biphasic stimulation pulse, allowing both nerves time to recover from their respective refractory period and to be activated again. During the stimulation pulse segment P2B, the nerve Y 414 under electrode B 404 is activated by electrical stimulation with intensity IN2B=IC*DC. Similarly, the nerve X 412 under electrode A 402 is activated during the stimulation pulse segment P2A with intensity IN2A=IA*DA. Again the effective charge CE delivered by the biphasic stimulation pulse using the electrode configuration of FIG. 4 is the same as the total pulse charge of (IC*DC)+(IA*DA) of this biphasic pulse. Therefore, the effective charge for each biphasic pulse increases to (IC*DC)+(IA*DA) with the novel electrode arrangement of FIG. 4, which is significantly greater than the effective charge IC*DC using the electrode arrangement 245 of FIG. 2.


Other electrode placements have also been considered. More than one electrode can be connected to the anode and cathode connectors of the TENS stimulator unit. Electrodes may also be placed on the body in such a manner that the nerves underneath the electrodes connected to the cathode terminal are also partially under the electrodes connected to the anode terminal. Additionally, not all electrodes need to be connected to either cathode or anode terminals during stimulation. Electrode array 421 in FIG. 4 provides an example. Electrodes A1422 and B1424 are first connected to the cathode and anode terminals respectively to transmit one or more biphasic pulses. Then electrodes A2423 and B2425 are connected to the cathode and anode terminals for the next one or several biphasic pulses. Then electrode A1422 and B2425 are connected to the cathode and anode terminals again. Then electrodes A2423 and B1424 are connected to the cathode and anode terminals again. One advantage of alternating the electrode connections may be a reduction of nerve habituation as the relative timing of the nerve pulses 426 and 427 (traveling along the two nerve fiber bundles X 412 and Y 414) becomes variable.


In a preferred embodiment, the target nerve which is to be stimulated is a peripheral sensory nerve. In another preferred embodiment, the target nerve is a cutaneous branch of a mixed motor and sensory nerve.



FIG. 5 shows an illustrative example of the voltage profile VCS(t) 530 across the current source 306 corresponding to the biphasic stimulation pulse 510. Voltage VCS(t) starts out at VP when t<t1 because voltages on all other components to the right of high voltage circuit 310 are zero as a result of zero current amplitude. At time t=t1, there is an immediate voltage drop 531 across the resistive components RS 352 and RI 355 (FIG. 3) due to stimulation current. Between the time interval t1≤t≤t2, the capacitive component CP 351 (FIG. 3) is being charged and the voltage across the load 350 causes a further gradual drop 532 of the voltage VCS(t). As long as minimum voltage 541 of VCS(t) stays above VCSmin, or VCS(t2)≥VCSmin, the current source will function properly during the first phase 514 of the biphasic pulse and deliver stimulation at the required current amplitude IC 512. At time instance t=t2, the current source 306 is turned off and any voltage across the resistive components RS and RI will become zero, causing a sudden increase 533 of VCS(t). During the time period t2<t<t3, the current source 306 remains off and the capacitive component CP 351 (FIG. 3) in the load 350 discharges slightly through the resistive component RP 353 (FIG. 3), causing a slight increase 534 of VCS(t). In a preferred embodiment, the delay δ(=t3−t2) 515 is set to 100 microseconds. At time instance t=t3, the load is reversed so that the original voltage drop in the direction from point T to point W in the load 350 becomes a voltage increase from point W to point T since voltage across the capacitor CP 351 (FIG. 3) cannot be changed instantaneously. As a result, the voltage VCS(t) across the current source 306 experiences a sudden increase 535 to a level usually above VP. Between the time interval t3<t<t4, the capacitive component CP is being charged and the voltage across the load 350 causes another gradual drop 536 of the voltage VCS(t). Again, as long as the minimum voltage 542 of VCS(t) stays above VCSmin, or VCS(t4)≥VCSmin, the current source will function properly during the second phase 516 of the biphasic pulse and deliver stimulation at the required current amplitude IA 518.


If the voltage VP at output terminal 309 of the high voltage circuit 310 is set too low, the voltage VCS(t) 530 across the current source 306 may not stay above its minimum voltage requirement VCSmin during the first phase of the pulse, or the second phase of the pulse, or both phases of the pulse. When the voltage VCS(t) falls below VCSmin, the current source may not be able to deliver the stimulation current at the required amplitude. FIG. 6 provides an illustrative example of the actual current pulse delivered 550 compared with the targeted stimulation current pulse 510. In this case, the first phase of the stimulation current pulse 552 fails to maintain the targeted stimulation current amplitude IC during the entire first phase of the biphasic stimulation pulse while the second phase of the stimulation current pulse 556 matches the targeted stimulation current amplitude IA throughout the entire second phase of the biphasic stimulation pulse. At time instance tC 553, the voltage VCS(t) falls below the threshold VCSmin because of the voltage increase across the capacitor CP (351 in FIG. 3) as a result of the capacitor being charged by the stimulation current IC. Actual stimulation current amplitude can be monitored via voltage readings from the resistor R1 as described above. If the actual stimulation current amplitude is not maintained at the same level throughout the entire phase duration, its stimulation intensity is no longer IC*DC. The actual stimulation intensity is the size of the shaded area 552 and can be approximated by a summation of a series of stimulation current amplitude measurements multiplied by the time interval between the consecutive current measurements. The shaded area 522 sometimes is referred to as the actual charge delivered by the stimulator during the first phase. In one embodiment, if the actual charge delivered is 10% (error percentage) smaller than the target charge IC*DC, the voltage VP is adjusted higher by an amount proportional to the error percentage value.


The voltage VP at output terminal 309 of the high voltage circuit 310 is regulated so that it stays as low as possible while maintaining the integrity of the stimulation pulse. In one embodiment, the integrity of the stimulation pulse is defined as the amplitude of the stimulation current I(t) of the biphasic stimulation pulse 510 being within a predetermined percentage of the target value IC for all t1≤t≤t2 and the target value IA for all t3≤t≤t4. An example of this predetermined percentage value is 95%. In another embodiment, the integrity of the stimulation pulse is defined as the intensity INCA 552 being within a predetermined percentage of the target intensity value INCT=IC*DC. An example of this predetermined percentage value is 90%. The actual amplitude of the stimulation current delivered can be measured via the voltage drop VI(t) across the resistor RI 355 over time.



FIG. 7 shows a flowchart of a high voltage control algorithm to regulate the high voltage VP. The actual amplitude of the stimulation current delivered I(t) can be measured via voltage VI across the resistor RI 355. Step 610 determines the actual stimulation current amplitude. Depending upon the exact definition of the pulse integrity, the most recent current amplitude or the integration of current amplitude measurements are obtained in step 620. The pulse integrity value is compared against appropriate threshold values to determine whether the pulse integrity is acceptable in step 630. If the integrity is not OK, the target value of the high voltage circuit output VP is increased through step 640 and the stimulation current amplitude is measured again at a pre-determined time interval. If the integrity is found to be OK in step 630, then the voltage VCS(t)=VC(t)−VI(t) is obtained in step 650. If the voltage exceeded the minimum threshold VCSmin, then the target value of the high voltage circuit output VP is decreased through step 660. In a preferred embodiment, VCSmin=1 Volt.


As seen in FIG. 5, the voltage VCS(t) decreases during the first phase 514 of the biphasic stimulation pulse and during the second stimulation phase 516 of the biphasic stimulation pulse. The sizes of the decreases 532 and 536 are proportional to the stimulation intensity IC*DC and IA*DA, respectively. For the first phase 514 of the biphasic pulse, the stimulation intensity is limited by VP−IC(RS+RI)−VCSmin, or the maximum voltage drop possible on the capacitor CP 351 within the load 350. However, the stimulation intensity upper limit for the second phase 516 of the biphasic pulse is twice as large as that for the first phase 514 of the biphasic pulse: 2*(VP−IC(RS+RI)−VCSmin). This is because the voltage on the capacitor CP is added to VP at time instance t=t3 so as to provide the starting voltage at the cathode terminal 303. Thus, the upper limit of the stimulation intensity for the second phase 516 of the biphasic pulse is twice as large as the upper limit of the stimulation intensity for the first phase 514 of the biphasic pulse. This phenomenon is sometimes referred to as the “voltage multiplier effect”. In practice, the value of the voltage multiplier effect is smaller than 2 due to discharge of the capacitor CP during the time period t2≤t≤t3 and leakage currents in the stimulator circuit.


The amplitude and duration parameters of each phase 514, 516 of the biphasic pulse can be independently specified. In one embodiment, IC (the stimulation current amplitude of the first phase) and IA (the stimulation current amplitude of the second phase) are set to one common value, and DC (the duration of the first phase) and DA (the duration of the second phase) are set to another common value. This configuration is the traditional biphasic symmetrical waveform. In another embodiment, IC and IA are set to the same value, but DA is set to be longer than DC in order to take advantage of the aforementioned voltage multiplier effect of the stimulator circuit (which is due to the electric charge accumulated in the capacitor CP during the first phase of the biphasic pulse). This configuration is a biphasic asymmetrical waveform.


In yet another embodiment, the amplitude of the second phase IA is set to a value higher than IC so that QC=IC*DC is the same as QA=IA*DA (thus DA<DC). Setting IA higher than IC may not require a higher target value for high voltage circuit output VP because of the aforementioned voltage multiplier effect. Being able to set IA higher, without requiring a higher output voltage VP, has several advantages. One of these advantages is to allow more effective stimulation of the nerve due to the well-known strength-duration relationship governing nerve stimulation efficacy. The charge required to stimulate a nerve fiber, QTH, increases linearly with the stimulation duration D as follows

QTH=b*(D+c)

where b and c are constants called the rheobase and chronaxie, respectively. These constants are influenced by many factors that include the biophysical properties of the nerve fiber being stimulated, the characteristics of the intervening tissue between the electrode and nerve fiber, and the characteristics of the stimulation waveform. However, in all cases b>1 and c>0. Therefore, the same nerve fiber will have a lower QTH if it is subject to a stimulation pulse with a higher amplitude I and shorter duration D. In other words, stimulation pulses with the same intensity, but a shorter duration, are more effective than those with a longer duration.


In yet another embodiment, both amplitude IA and duration DA of the second phase of the biphasic pulse can be set higher than their corresponding values of the first phase without the need to increase the high voltage circuit output VP due to the aforementioned voltage multiplier effect.


In yet another embodiment, the amplitude of the second phase IA is set to a different value, for example in a random fashion, for consecutive biphasic pulses such that all amplitude values are within a range. The lower limit of the range can be the amplitude of the first phase IC and the upper limit of the range can be the highest value without increasing the high voltage circuit output VP requirement that is needed to support the first phase of the biphasic pulse stimulation. The duration of the second phase of the biphasic stimulation pulse can similarly be set to a range of values. An advantage of varying the intensity of the second phase of the biphasic pulse is to reduce nerve habituation and to increase TENS analgesia effectiveness.


With the same high voltage circuit output VP, the second phase of the biphasic stimulation pulse is capable of stimulating a nerve whose QTH may exceed what the first phase of the biphasic stimulation pulse may be able to do, even when VP=VPmax, where VPmax is the maximum output voltage that can be delivered by the high voltage circuit 310. In another embodiment, the high voltage circuit output VP is adjusted to a level only high enough to guarantee the integrity of the second phase of the biphasic stimulation pulse. At least two advantages are obtained with such an approach. Firstly, by leveraging the voltage multiplier effect at the second phase of the biphasic pulse, some pain relief can be provided to users of the TENS device whose QTH cannot be supported with the existing TENS hardware design specifications if only monophasic pulses are used. Secondly, battery life can be extended inasmuch as the high voltage circuit output is lower than what would otherwise be required.


If the amplitude of the stimulation current remains the same for both phases of the biphasic stimulation pulse (i.e., IC=IA=I), one can optimize the duration ratio between the two phases of the biphasic pulse to maximize the total intensity of the biphasic pulse for a given high voltage VP. For simplicity, we assume DC=α*DS and DA=(1−α)*DS, where DS is the summation of the first and second phases of the biphasic pulse. Thus a represents the ratio of the duration of the first phase of the biphasic pulse to the sum of the durations of the first phase of the biphasic pulse plus the second phase of the biphasic pulse. Consequently, the total intensity delivered would be I*DS. Recall earlier that we have shown that the voltage over the current source 306 is VP−I(RS+RI)−VEC, where VEC is the voltage across the capacitor CP as a result of a current pulse with amplitude I and duration αDS:VEC=α*I*DS. The minimum required high voltage output is VPmin=VEC+I(RS+RI)+VCSmin. Ignoring the voltage change 534 due to capacitor CP discharge during the inter-phase interval 6515 (FIG. 5), the voltage over the current source 306 at the beginning of second phase is (at t=

VPmin+VEC−I*(RS+RI)=2VEC+VCSmin


The maximum voltage change ΔVEA,max over the capacitor 351 during the second phase of the biphasic pulse must satisfy

2VEC+VCSmin−ΔVEA,max≥VCSmin or ΔVEA,max≤2VEC

Utilizing the aforementioned Eq. (1), we have

(1−α)*I*DS≤2*I*DS or α≥⅓.


In a preferred embodiment, the value α is set to 0.36. Using the approximation of I(RS+RI)+VCSmin≈γVEC, where γ<<1.0 is a constant, we have the minimum required high voltage for a given a as

VPmin=(1+γ)*VEC=(1+γ)*α*I*DS

For a fixed effective charge (total stimulation intensity) I*DS, the minimum high voltage setting at α=0.36 is









0
.
3


6


0
.
5


=

7

2

%






of what would be required for a symmetric biphasic pulse (i.e., a biphasic pulse having equal duration for both phases, or α=0.5). As a result, battery life is expected to be 39% longer under the asymmetric pulse duration case (α=0.36) than under the symmetric pulse duration case (α=0.5) when both cases deliver the same effective charge I*DS.


Achieving Net Zero Charge Accumulation by Reversing the Polarity of the Biphasic Pulses

In one form of the present invention, each biphasic pulse has unbalanced total charge for its two phases. See, for example, the biphasic waveform shown in FIG. 5. The total charge of the first phase of the biphasic pulse is not balanced by the total charge of the second phase of the biphasic pulse: IC*DC≠IA*DA. Accordingly, in one preferred embodiment of the present invention, the polarity of the leading phase of consecutive biphasic pulses alternates so as to allow balanced charge to be delivered to each electrode skin contact area. More particularly, and looking at FIG. 4, the total (negative) charge flowing into the skin area under electrode A 402 is IC*DC during the first phase HA of the biphasic pulse and the total (negative) charge flowing out of the same skin area is IA*DA during the second phase P1B of the biphasic pulse. The second biphasic pulse has the polarity of its leading phase P2B reversed when compared with the polarity of the leading phase P1A of the first biphasic pulse. Consequently, the total (negative) charge flowing out of the skin area is IC*DC during the first phase P2B of the biphasic pulse and the total (negative) charge flowing into the skin area is IA*DA during the second phase P2A of the biphasic pulse. So the net charge is effectively balanced over a span of two biphasic pulses. Similarly, there is no net charge accumulation in the skin areas under electrode B 404.


Instead of alternating the polarity of the leading phase for every biphasic pulse (i.e., as shown in FIG. 4), the frequency of alternating the polarity of the leading phase of the biphasic pulses can be set to a lower value as long as the zero net charge accumulation is maintained across a reasonable period of time. In other words, the polarity of the leading phase of the biphasic pulses may be changed every two pulses, or every three pulses, or every four pulses, etc., so long as there is no net charge accumulation over a selected period of time (which is not so long as to result in adverse skin reactions under the electrodes). In one preferred embodiment, polarity alternating occurs every two biphasic pulses.


Experimental Data Demonstrating Benefits of Asymmetric Biphasic Pulse Stimulation

To demonstrate the benefits of the asymmetric pulse duration approach disclosed herein, ten healthy subjects were recruited and consented to participate in a study to compare the effectiveness of two different biphasic pulse stimulation patterns. Pattern A was the symmetric biphasic pulse pattern wherein both phases of the biphasic pulse had the same amplitude and duration, e.g., such as the biphasic pulse pattern shown in FIG. 2. The duration was fixed at 100 microseconds and amplitude was allowed to be adjusted by each subject to evoke the first sensation of electrical stimulation. Pattern B was the asymmetric biphasic pulse pattern wherein the second phase of the biphasic pulse had a longer duration (180 microseconds) than the first phase of the biphasic pulse (100 microseconds), e.g., such as the biphasic pulse pattern shown in FIG. 5. The amplitude of both phases of the Pattern B asymmetric biphasic pulse pattern was kept the same and allowed to be adjusted by each subject so as to evoke the same first sensation of electrical stimulation as for Pattern A. Subjects were blinded to the stimulation pattern used and carried out the sensation threshold discovery process three times for each stimulation pattern. During each trial, the subject indicated the minimum stimulation pulse amplitude that evoked the first sensation of electrical stimulation. Table 1 summarizes the study results. For each subject, the three identified stimulation pulse amplitudes (in milliamps) were averaged for Pattern A and Pattern B, respectively. Among the ten test subjects, the minimum stimulation current amplitude to evoke a first sensation of electrical stimulation was 14%-35% lower for asymmetric pulse pattern B than that for symmetric pulse pattern A. Since both pulse patterns had the same duration in the first phase of the biphasic pulse, the reduction in stimulation current amplitude required to evoke the first sensation can only be attributed to longer duration of the second phase of the asymmetric pulse Pattern B. Earlier analyses indicate that the minimum high voltage VP required will be lower if the first phase current amplitude is lower. Because of the voltage multiplier effect, the high voltage requirement for any pulse with a second phase duration less than 2-times the first phase duration will be approximately the same as that for the first phase.













TABLE 1





SubjID
Pattern B
Pattern A
Difference (mA)
Difference (%)



















1
10.0
14.8
−4.8
−32.2%


2
12.1
16.9
−4.7
−28.2%


3
13.9
21.3
−7.3
−34.5%


4
9.1
13.6
−4.5
−32.9%


5
17.5
22.3
−4.8
−21.6%


6
12.5
14.5
−2.1
−14.4%


7
9.8
14.3
−4.4
−31.0%


8
11.8
15.9
−4.1
−25.8%


9
14.0
16.6
−2.6
−15.7%


10
7.1
10.3
−3.2
−30.7%


Mean



−26.7%





Comparison of minimum current amplitude required to evoke first stimulation sensation in human subjects. Pattern A refers to biphasic pulse with same pulse duration for both phases (100 μs). Pattern B refers to biphasic pulse with the pulse duration for second phase (180 μs) longer than the first pulse duration (100 μs). Amplitude for both phases are the same in either pulse patterns. Results are the average of three trials.






Direct Muscle Stimulation Using Asymmetric Biphasic Electrical Pulses with an Alternating Polarity of the Leading Phase of the Pulses

Electrical pulses can also be used to stimulate muscles directly so as to cause muscle contractions. Electrical pulses are delivered through electrodes on the skin. Instead of placing the electrodes so as to overlay peripheral nerves, the electrodes are placed on the skin in direct proximity to the muscles which are to be stimulated. Electrical muscle stimulation (EMS) can be used to improve muscle strength in athletes, to prevent muscle atrophy in patients with musculoskeletal injuries, and to provide external muscle control when the nerve supply to the muscle is compromised.


Portable EMS devices face similar challenges to TENS devices in terms of battery life and stimulation intensity. Applying asymmetric biphasic stimulation pulses in EMS can overcome these challenges by leveraging charge build-up during the first phase of the biphasic stimulation pulse in order to deliver more powerful stimulation during the second phase of the biphasic stimulation pulse. Delivering stronger stimulation pulses with a higher amplitude or a longer duration in the second phase of the biphasic stimulation pulse, without requiring an increase in the output of the high-voltage circuit, will lead to savings in battery life. Alternating the polarity of the leading phase of the biphasic electrical pulses allows the muscles under each electrode to receive the same total stimulation intensity. Alternating the polarity of the leading phases of the biphasic electrical pulses also ensures zero net charge flowing into each electrode even when asymmetric biphasic pulses are used.


Modifications of the Preferred Embodiments

It should be understood that many additional changes in the details, materials, steps and arrangements of parts, which have been herein described and illustrated in order to explain the nature of the present invention, may be made by those skilled in the art while still remaining within the principles and scope of the invention.

Claims
  • 1. Apparatus for providing transcutaneous electrical muscle stimulation to a user, said apparatus comprising: a stimulation unit for electrically stimulating one or more muscles using an asymmetric biphasic electrical pulse from a current source, wherein during the first phase and the second phase of an asymmetric biphasic electrical pulse, said stimulation unit uses a same voltage level at an anode, wherein said stimulation unit delivers a larger amount of electrical charge in the second phase of the asymmetric biphasic electrical pulse than the amount of electrical charge delivered in the first phase of the asymmetric biphasic electrical pulse, and wherein the same anode voltage level is selected to maintain a minimum voltage required for the current source during the first phase of the asymmetric biphasic electrical pulse;a control unit for controlling the stimulation delivered by said stimulation unit; andan electrode array connectable to said stimulation unit, said electrode array comprising a substrate and at least first and second electrodes.
  • 2. Apparatus according to claim 1 wherein the at least first and second electrodes are mounted to said substrate with a predetermined arrangement, so that when said substrate is placed on one location of the user's body, said first electrode overlays a first muscle underneath the electrode array but not a second muscle underneath the electrode array and said second electrode overlays the second muscle underneath the electrode array but not the first muscle underneath the electrode array.
  • 3. Apparatus according to claim 2 wherein the said first electrode and said second electrode both overlay a third muscle underneath the electrode array.
  • 4. Apparatus according to claim 1 wherein said control unit is configured to cause said stimulation unit to deliver discrete asymmetric biphasic electrical pulses.
  • 5. Apparatus according to claim 4 wherein the polarity of the first phase of the discrete asymmetric biphasic electrical pulses varies.
  • 6. Apparatus according to claim 4 wherein the polarity of the first phase of each discrete asymmetric biphasic electrical pulse varies so as to ensure that an equal amount of positive and negative charges flow into each electrode within a predetermined time period.
  • 7. Apparatus according to claim 4 wherein the discrete asymmetric biphasic electrical pulses are delivered at a constant frequency.
  • 8. Apparatus according to claim 4 wherein the discrete asymmetric biphasic electrical pulses are delivered at a random frequency.
  • 9. Apparatus according to claim 1 wherein said control unit controls the anode voltage of said stimulation unit.
  • 10. Apparatus according to claim 9 wherein said control unit controls said anode voltage based on at least one of the following: (i) the cathode voltage, and (ii) measurements of the asymmetric biphasic electrical pulses.
  • 11. Apparatus according to claim 1 wherein said control unit controls the amplitude and duration of the first and second phases of the asymmetric biphasic electrical pulses.
  • 12. Apparatus according to claim 11 wherein the amplitude of the second phase of said asymmetric biphasic electrical pulses is the same as that of the first phase of said asymmetric biphasic electrical pulses.
  • 13. Apparatus according to claim 11 wherein the amplitude of the second phase of said asymmetric biphasic electrical pulses is greater than that of the first phase of said asymmetric biphasic electrical pulses.
  • 14. Apparatus according to claim 11 wherein the duration of the second phase of said asymmetric biphasic electrical pulses is the same as that of the first phase of said asymmetric biphasic electrical pulses.
  • 15. Apparatus according to claim 11 wherein the duration of the second phase of said asymmetric biphasic electrical pulses is greater than that of the first phase of said asymmetric biphasic electrical pulses.
  • 16. Apparatus for providing transcutaneous electrical muscle stimulation to a user, said apparatus comprising: a stimulation unit for electrically stimulating one or more muscles using an asymmetric biphasic electrical pulse from a current source, wherein during the second phase of the asymmetric biphasic electrical pulse, said stimulation unit uses an anode voltage level that is no greater than the anode voltage level used during the first phase of the asymmetric biphasic electrical pulse, and wherein said stimulation unit delivers a larger amount of electrical charge in the second phase of the asymmetric biphasic electrical pulse than the amount of electrical charge delivered in the first phase of the asymmetric biphasic electrical pulse;a control unit for controlling the stimulation delivered by said stimulation unit; andan electrode array connectable to said stimulation unit, said electrode array comprising a substrate and at least first and second electrodes.
  • 17. A method for providing transcutaneous electrical muscle stimulation therapy to a user, said method comprising: providing a stimulation unit for generating asymmetric biphasic electrical pulses, wherein the stimulation unit delivers a larger amount of electrical charge in the second phase of an asymmetric biphasic electrical pulse than the amount of electrical charge delivered in the first phase of the asymmetric biphasic electrical pulse, and wherein a same anode voltage level is used by the stimulation unit during the first and second phases of the asymmetric biphasic electrical pulse;providing an electrode array connectable to said stimulation unit, said electrode array comprising a substrate and at least first and second electrodes; andusing said stimulation unit and said electrode array to apply asymmetric biphasic electrical pulses to the skin of a user.
  • 18. A method according to claim 17 wherein the at least first and second electrodes are mounted to said substrate with a predetermined arrangement, so that when said substrate is placed on one location of the user's body, said first electrode overlays a first muscle underneath the electrode array but not a second muscle underneath the electrode array and said second electrode overlays the second muscle underneath the electrode array but not the first muscle underneath the electrode array.
  • 19. A method according to claim 18 wherein the first electrode activates the first muscle during the first phase of the asymmetric biphasic electrical pulse and the second electrode activates the second muscle during the second phase of the asymmetric biphasic electrical pulse.
  • 20. A method according to claim 17 wherein said stimulation unit delivers a sequence of discrete asymmetric biphasic electrical pulses.
  • 21. A method according to claim 20 wherein said asymmetric biphasic electrical pulses are delivered at a random frequency, wherein said random frequency is within a predetermined range.
  • 22. A method according to claim 20 wherein said asymmetric biphasic electrical pulses vary the polarity of the first phase of the asymmetric biphasic electrical pulses.
  • 23. A method according to claim 22 wherein the pattern of variations of the first phases of the asymmetric biphasic electrical pulses ensures that an equal amount of positive and negative charges flow into each electrode within a predetermined time period.
  • 24. A method according to claim 17 wherein said stimulation unit controls the amplitude of the two phases of the asymmetric biphasic electrical pulses independently.
  • 25. A method according to claim 17 wherein said stimulation unit controls the duration of the two phases of the asymmetric biphasic electrical pulses independently.
  • 26. A method according to claim 17 wherein said stimulation unit controls the anode voltage based on at least one of the following: (i) the cathode voltage, and (ii) measurements of the asymmetric biphasic electrical pulses.
  • 27. A method for providing transcutaneous electrical muscle stimulation therapy to a user, said method comprising: providing a stimulation unit for generating asymmetric biphasic electrical pulses, wherein the stimulation unit delivers a larger amount of electrical charge in the second phase of an asymmetric biphasic electrical pulse than the amount of electrical charge delivered in the first phase of the asymmetric biphasic electrical pulse, and wherein the stimulation unit uses an anode voltage level in the second phase that is no greater than the anode voltage level used in the first phase;providing an electrode array connectable to said stimulation unit, said electrode array comprising a substrate and at least first and second electrodes; andusing said stimulation unit and said electrode array to apply asymmetric biphasic electrical pulses to the skin of a user.
REFERENCE TO PENDING PRIOR PATENT APPLICATIONS

This patent application is a continuation of prior U.S. patent application Ser. No. 16/175,212, filed Oct. 30, 2018 by Neurometrix, Inc. for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION USING NOVEL UNBALANCED BIPHASIC WAVEFORM AND NOVEL ELECTRODE ARRANGEMENT, which in turn a continuation of prior U.S. patent application Ser. No. 15/350,261, filed Nov. 14, 2016 by Neurometrix, Inc. for TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION USING NOVEL UNBALANCED BIPHASIC WAVEFORM AND NOVEL ELECTRODE ARRANGEMENT, which in turn is a continuation-in-part of prior U.S. patent application Ser. No. 14/610,757, filed Jan. 30, 2015 by NeuroMetrix, Inc. and Shai N. Gozani et al. for APPARATUS AND METHOD FOR RELIEVING PAIN USING TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, which patent application is a continuation of prior U.S. patent application Ser. No. 13/678,221, filed Nov. 15, 2012 by NeuroMetrix, Inc. and Shai N. Gozani et al. for APPARATUS AND METHOD FOR RELIEVING PAIN USING TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, which in turn claims benefit of (i) prior U.S. Provisional Patent Application Ser. No. 61/560,029, filed Nov. 15, 2011 by Shai N. Gozani for SENSUS OPERATING MODEL; and (ii) prior U.S. Provisional Patent Application Ser. No. 61/657,382, filed Jun. 8, 2012 by Shai N. Gozani et al. for APPARATUS AND METHOD FOR RELIEVING PAIN USING TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION. The six (6) above-identified patent applications are hereby incorporated herein by reference.

US Referenced Citations (281)
Number Name Date Kind
1741962 Theodoropulos Dec 1929 A
4290431 Herbert et al. Sep 1981 A
D263869 Sumiyasu Apr 1982 S
4503863 Katims Mar 1985 A
4605010 McEwen Aug 1986 A
4738250 Fulkerson et al. Apr 1988 A
4989605 Rossen Feb 1991 A
5048523 Yamasawa et al. Sep 1991 A
5063929 Bartelt et al. Nov 1991 A
D323561 Bartelt et al. Jan 1992 S
5121747 Andrews Jun 1992 A
5169384 Bosniak et al. Dec 1992 A
D342571 Givens, Sr. Dec 1993 S
D346029 Shalvi Apr 1994 S
5350414 Kolen Sep 1994 A
5429589 Cartmell et al. Jul 1995 A
5479939 Ogino Jan 1996 A
5487759 Bastyr et al. Jan 1996 A
5562718 Palermo Oct 1996 A
5806522 Katims Sep 1998 A
D411887 Agarwala Jul 1999 S
5948000 Larsen et al. Sep 1999 A
6099488 Hung Aug 2000 A
6132387 Gozani et al. Oct 2000 A
6141587 Mower Oct 2000 A
6161044 Silverstone Dec 2000 A
D443362 Storp Jun 2001 S
6266558 Gozani et al. Jul 2001 B1
D450313 Koinuma Nov 2001 S
6430450 Bach-y-Rita et al. Aug 2002 B1
D462772 Lamping et al. Sep 2002 S
6456884 Kenney Sep 2002 B1
6611789 Darley Aug 2003 B1
6662051 Eraker et al. Dec 2003 B1
D484984 Takizawa et al. Jan 2004 S
D534871 Larsen Jan 2007 S
D541042 Andre et al. Apr 2007 S
D547454 Hsieh Jul 2007 S
D566383 Harris et al. Apr 2008 S
D584414 Lash et al. Jan 2009 S
D592200 Liu May 2009 S
D598556 Chen Aug 2009 S
D600352 Cryan Sep 2009 S
D607198 Andre et al. Jan 2010 S
D609353 Cryan Feb 2010 S
7668598 Herregraven et al. Feb 2010 B2
D611611 Sachi et al. Mar 2010 S
D615526 Andre et al. May 2010 S
7720548 King May 2010 B2
7725193 Chu May 2010 B1
7787946 Stahmann et al. Aug 2010 B2
D625016 Potts et al. Oct 2010 S
D625829 Arbesman et al. Oct 2010 S
D629115 Robertson Dec 2010 S
7887493 Stahmann et al. Feb 2011 B2
D636881 Clemens et al. Apr 2011 S
D637988 Jinkinson May 2011 S
8108049 King Jan 2012 B2
8121702 King Feb 2012 B2
8131374 Moore et al. Mar 2012 B2
D658302 Nixon Apr 2012 S
8284070 Chaudhari et al. Oct 2012 B2
D677792 Vandiver Mar 2013 S
D680735 Itabashi et al. Apr 2013 S
8421642 McIntosh et al. Apr 2013 B1
D687951 Della Torre et al. Aug 2013 S
D688707 Vincent et al. Aug 2013 S
D704848 Thomas et al. May 2014 S
D705428 Cheney et al. May 2014 S
D712045 Thornton Aug 2014 S
D712052 Thomas et al. Aug 2014 S
D713049 Shah Sep 2014 S
8825175 King Sep 2014 B2
D716457 Brefka et al. Oct 2014 S
8862238 Rahimi et al. Oct 2014 B2
D716963 Yosef et al. Nov 2014 S
8948876 Gozani et al. Feb 2015 B2
D732682 Porat Jun 2015 S
D735873 Brefka et al. Aug 2015 S
9168375 Rahimi et al. Oct 2015 B2
D744661 Rizzi Dec 2015 S
D745975 Igaue et al. Dec 2015 S
D750263 Shigeno et al. Feb 2016 S
D750798 Yosef et al. Mar 2016 S
9282287 Marsh Mar 2016 B1
9282897 Ross, Jr. et al. Mar 2016 B2
D754355 Ganapathy et al. Apr 2016 S
D754973 Danze et al. May 2016 S
D757292 Chen May 2016 S
D758605 Chen Jun 2016 S
D758606 Chen Jun 2016 S
D759262 Chen Jun 2016 S
D759263 Chen Jun 2016 S
D759958 Requa Jun 2016 S
D762628 Yoon et al. Aug 2016 S
D762872 Chen Aug 2016 S
D767775 Gilmer et al. Sep 2016 S
9452287 Rosenbluth et al. Sep 2016 B2
9474898 Gozani et al. Oct 2016 B2
D774654 Anderson Dec 2016 S
D775361 Vosch et al. Dec 2016 S
D778453 Knaus et al. Feb 2017 S
D779677 Chen Feb 2017 S
9561397 Zaki Feb 2017 B2
D784544 Dudkiewicz et al. Apr 2017 S
D784546 Gordon Apr 2017 S
D784946 Jun et al. Apr 2017 S
D788056 Choi et al. May 2017 S
9656070 Gozani et al. May 2017 B2
D789546 Matfus et al. Jun 2017 S
D789547 Matfus et al. Jun 2017 S
D791333 Wilson Jul 2017 S
D792363 Kim et al. Jul 2017 S
9700724 Liu et al. Jul 2017 B2
D794331 Grote Aug 2017 S
9731126 Ferree et al. Aug 2017 B2
D798170 Toth et al. Sep 2017 S
D801542 Anderson Oct 2017 S
D802780 Hsu Nov 2017 S
9827420 Ferree et al. Nov 2017 B2
D806669 Kangasmaa et al. Jan 2018 S
D810311 Chen Feb 2018 S
D810843 Karvandi Feb 2018 S
D810952 Hsu Feb 2018 S
D811729 Bysshe Mar 2018 S
D813405 Ho Mar 2018 S
D813407 Chen Mar 2018 S
D813408 Chen Mar 2018 S
D821592 Pham et al. Jun 2018 S
D828569 Mercuro Sep 2018 S
D829182 Li Sep 2018 S
10076662 Tuan Sep 2018 B2
D830565 Xu Oct 2018 S
D831017 Choe et al. Oct 2018 S
D831221 Smith Oct 2018 S
D831335 Crease Oct 2018 S
D832230 Lee et al. Oct 2018 S
D834719 Theriot et al. Nov 2018 S
D836788 Peng Dec 2018 S
D837394 Cryan et al. Jan 2019 S
10279179 Gozani et al. May 2019 B2
10335595 Ferree et al. Jul 2019 B2
D857910 Cryan et al. Aug 2019 S
D861903 Cryan et al. Oct 2019 S
D861904 Ho Oct 2019 S
D862716 Cryan et al. Oct 2019 S
D865986 Cryan et al. Nov 2019 S
D879983 Wang Mar 2020 S
20020010497 Merfeld et al. Jan 2002 A1
20030023192 Foxlin Jan 2003 A1
20030074037 Moore et al. Apr 2003 A1
20030114892 Nathan et al. Jun 2003 A1
20030208246 Kotlik et al. Nov 2003 A1
20040049241 Campos Mar 2004 A1
20040122483 Nathan et al. Jun 2004 A1
20050059903 Izumi Mar 2005 A1
20050080463 Stahmann et al. Apr 2005 A1
20050097970 Nurse May 2005 A1
20050131317 Oddsson et al. Jun 2005 A1
20050234525 Phillips Oct 2005 A1
20050283204 Buhlmann et al. Dec 2005 A1
20060052788 Thelen et al. Mar 2006 A1
20060085047 Unsworth et al. Apr 2006 A1
20060085049 Cory et al. Apr 2006 A1
20060089683 Hagglof et al. Apr 2006 A1
20060095088 De Ridder May 2006 A1
20060173507 Mrva et al. Aug 2006 A1
20060190057 Reese Aug 2006 A1
20060251334 Oba et al. Nov 2006 A1
20070021786 Pamis et al. Jan 2007 A1
20070060922 Dreyfuss Mar 2007 A1
20070203435 Novak Aug 2007 A1
20070203547 Costello et al. Aug 2007 A1
20070276449 Gunter et al. Nov 2007 A1
20080009772 Tyler et al. Jan 2008 A1
20080077192 Harry et al. Mar 2008 A1
20080146980 Rousso et al. Jun 2008 A1
20080147143 Popovic et al. Jun 2008 A1
20080147146 Wahlgren et al. Jun 2008 A1
20080172102 Shalev Jul 2008 A1
20080312709 Volpe et al. Dec 2008 A1
20090030476 Hargrove Jan 2009 A1
20090076364 Libbus et al. Mar 2009 A1
20090082829 Panken et al. Mar 2009 A1
20090112214 Philippon et al. Apr 2009 A1
20090131993 Rousso et al. May 2009 A1
20090203972 Heneghan et al. Aug 2009 A1
20090240303 Wahlstrand et al. Sep 2009 A1
20090264789 Molnar et al. Oct 2009 A1
20090270947 Stone et al. Oct 2009 A1
20090326604 Tyler et al. Dec 2009 A1
20100004715 Fahey Jan 2010 A1
20100010585 Davis et al. Jan 2010 A1
20100042180 Mueller et al. Feb 2010 A1
20100057149 Fahey Mar 2010 A1
20100087903 Van Herk et al. Apr 2010 A1
20100094103 Kaplan et al. Apr 2010 A1
20100114257 Torgerson May 2010 A1
20100131028 Hsu et al. May 2010 A1
20100198124 Bhugra Aug 2010 A1
20100217349 Fahey Aug 2010 A1
20100241464 Amigo et al. Sep 2010 A1
20100274304 Wang et al. Oct 2010 A1
20110066209 Bodlaender et al. Mar 2011 A1
20110106213 Davis et al. May 2011 A1
20110166622 Crosson et al. Jul 2011 A1
20110190594 Heit et al. Aug 2011 A1
20110224665 Crosby et al. Sep 2011 A1
20110245711 Katra et al. Oct 2011 A1
20110257468 Oser et al. Oct 2011 A1
20110264171 Torgerson Oct 2011 A1
20110276107 Simon et al. Nov 2011 A1
20110282164 Yang et al. Nov 2011 A1
20120010680 Wei et al. Jan 2012 A1
20120108998 Molnar et al. May 2012 A1
20120123227 Sun et al. May 2012 A1
20120130449 Carlyon et al. May 2012 A1
20120303077 De Vincentiis Nov 2012 A1
20120319816 Al-Ali Dec 2012 A1
20130096641 Strother et al. Apr 2013 A1
20130116514 Kroner et al. May 2013 A1
20130158627 Gozani et al. Jun 2013 A1
20130197341 Grob et al. Aug 2013 A1
20130217998 Mahfouz et al. Aug 2013 A1
20130317333 Yang et al. Nov 2013 A1
20140005759 Fahey Jan 2014 A1
20140039450 Green et al. Feb 2014 A1
20140057232 Wetmore et al. Feb 2014 A1
20140081353 Cook et al. Mar 2014 A1
20140088192 Heller et al. Mar 2014 A1
20140107729 Sumners et al. Apr 2014 A1
20140163444 Ingvarsson et al. Jun 2014 A1
20140206976 Thompson et al. Jul 2014 A1
20140221797 Bailey et al. Aug 2014 A1
20140245784 Proud et al. Sep 2014 A1
20140245791 Proud et al. Sep 2014 A1
20140276549 Osorio Sep 2014 A1
20140296934 Gozani et al. Oct 2014 A1
20140296935 Ferree et al. Oct 2014 A1
20140309709 Gozani et al. Oct 2014 A1
20140336725 Nogueira Nov 2014 A1
20140336730 Simon et al. Nov 2014 A1
20140343625 O Laighin Nov 2014 A1
20140371547 Gartenberg et al. Dec 2014 A1
20140371814 Spizzirri et al. Dec 2014 A1
20140379045 Rahimi et al. Dec 2014 A1
20150045853 Alataris et al. Feb 2015 A1
20150100107 Kiani et al. Apr 2015 A1
20150157242 Sabesan Jun 2015 A1
20150157868 Franke et al. Jun 2015 A1
20150174402 Thomas et al. Jun 2015 A1
20150238094 Lai et al. Aug 2015 A1
20150272511 Najafi et al. Oct 2015 A1
20150306387 Kong et al. Oct 2015 A1
20150321000 Rosenbluth et al. Nov 2015 A1
20150328467 Demers et al. Nov 2015 A1
20150335288 Toth et al. Nov 2015 A1
20150335877 Jeffery et al. Nov 2015 A1
20160007931 Rubin et al. Jan 2016 A1
20160113551 Annegam et al. Apr 2016 A1
20160144174 Ferree et al. May 2016 A1
20160151628 Simon et al. Jun 2016 A1
20160189371 Krishna Rao et al. Jun 2016 A1
20160213924 Coleman et al. Jul 2016 A1
20160242646 Obma Aug 2016 A1
20160243359 Sharma Aug 2016 A1
20160367823 Cowan et al. Dec 2016 A1
20170056650 Cohen et al. Mar 2017 A1
20170188872 Hughes et al. Jul 2017 A1
20170209693 An et al. Jul 2017 A1
20170224990 Goldwasser et al. Aug 2017 A1
20170368345 Kong et al. Dec 2017 A1
20180000685 Maloney et al. Jan 2018 A1
20180028808 Ferree et al. Feb 2018 A1
20180132757 Kong et al. May 2018 A1
20180177996 Gozani et al. Jun 2018 A1
20180345014 Gozani et al. Dec 2018 A1
20190001135 Yoo et al. Jan 2019 A1
20190134393 Wong et al. May 2019 A1
20200179694 Kong et al. Jun 2020 A1
20200219615 Rabin et al. Jul 2020 A1
Foreign Referenced Citations (36)
Number Date Country
1665563 Sep 2005 CN
1919139 Feb 2007 CN
1926496 Mar 2007 CN
101557788 Oct 2009 CN
101626804 Jan 2010 CN
102202131 Sep 2011 CN
102355847 Feb 2012 CN
102740919 Oct 2012 CN
102010052710 May 2012 DE
0971653 Jan 2000 EP
1 985 277 Feb 2015 EP
61-171943 Oct 1986 JP
4-347140 Dec 1992 JP
9-117453 May 1997 JP
2000-167067 Jun 2000 JP
2005-34402 Feb 2005 JP
2005-81068 Mar 2005 JP
2006-68300 Mar 2006 JP
4185846 Sep 2008 JP
WO 9742999 Nov 1997 WO
WO 9964105 Dec 1999 WO
WO 03051453 Jun 2003 WO
WO 2004078132 Sep 2004 WO
WO 2007061746 May 2007 WO
WO 2008079757 Jul 2008 WO
WO 2008088985 Jul 2008 WO
WO 2009036313 Mar 2009 WO
WO 2011075179 Jun 2011 WO
WO 2011137193 Nov 2011 WO
WO 2012116407 Sep 2012 WO
WO 2013028960 Feb 2013 WO
WO 2014172381 Oct 2014 WO
WO 2015123373 Aug 2015 WO
WO 2016201366 Dec 2016 WO
WO 2018089655 May 2018 WO
WO 2020033883 Feb 2020 WO
Non-Patent Literature Citations (78)
Entry
Amazon, “Quell 2.0 Wearable Pain Relief Technology”, Sep. 15, 2018.http://www.amazon/com/Quell-Wearable-Pain-Relief-Technology/dp/B07DHW2MJJ/ref=cm_cr_arp_d_product_top? ie=UTF8. Shown on p. 1. (Year: 2018).
Amazon, “Quell Wearable Pain Relief Technology Starter Kit”, Oct. 18, 2017. http://www.amazon.com/Quell-Wearable-ReliefTechnology-Starter/dp/B075YVCLZT/ref=cm_cr_arp_d_product_top?ie=UTF8. Shown on p. 1. (Year: 2017).
Amft, O. et al., Sensing Muscle Activities with Body-Worn Sensors, Conference Paper, May 2006.
Ancoli-Israel, S. et al., The Role of Actigraphy in the Study of Sleep and Circadian Rhythms, Sleep, 2003, 26(3), p. 342-392.
Aurora, R. et al., The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults—An Update for 2012: Practice Parameters with an Evidence-Based Systematic Review and Meta-Analyses, Sleep, 2012, vol. 35, No. 8, p. 1039-1062.
Barbarisi, Manlio et al., Pregabalin and Transcutaneous Electrical Nerve Stimulation for Postherpetic Neuralgia Treatment, The Clinical Journal of Pain, Sep. 2010;26(7):567-572.
Bifulco, P. et al., A Stretchable, Conductive Rubber Sensor to Detect Muscle Contraction for Prosthetic Hand Control, The 6th IEEE International Conference on E-Health and Bioengineering—EHB 2017, Jun. 22-24, 2017, pp. 173-176.
Bjordal JM et al., Transcutaneous electrical nerve stimulation (TENS) can reduce postoperative analgesic consumption. A meta-analysis with assessment of optimal treatment parameters for postoperative pain, European Journal of Pain, 2003, vol. 7(2): 181-188.
Bloodworth DM et al., Comparison of stochastic vs. conventional transcutaneous electrical stimulation for pain modulation in patients with electromyographically documented radiculopathy, American Journal of Physical Medicine & Rehabilitation, 2004, vol. 83(8): 584-591.
Bonnet, M. et al., Recording and Scoring Leg Movements, Sleep, 1993, vol. 16, No. 8, p. 748-759.
Boyle, J. et al., Randomized, Placebo-Controlled Comparison of Amitriptyline, Duloxetine, and Pregabalin in Patients With Chronic Diabetic Peripheral Neuropathic Pain, Diabetes Care, 2012, vol. 35, p. 2451-2458.
Chandran P et al., Development of opioid tolerance with repeated transcutaneous electrical nerve stimulation administration, Pain, 2003, vol. 102: 195-201.
Chen CC et al., A comparison of transcutaneous electrical nerve stimulation (TENS) at 3 and 80 pulses per second on cold-pressor pain in healthy human participants, Clinical Physiology and Functioning Imaging, 2010, vol. 30(4): 260-268.
Chen CC et al., An investigation into the effects of frequency-modulated transcutaneous electrical nerve stimulation (TENS) on experimentally-induced pressure pain in healthy human participants, The Journal of Pain, 2009, vol. 10(10): 1029-1037.
Chen CC et al., Differential frequency effects of strong nonpainful transcutaneous electrical nerve stimulation on experimentally induced ischemic pain in healthy human participants, The Clinical Journal of Pain, 2011, vol. 27(5): 434-441.
Chen CC et al., Does the pulse frequency of transcutaneous electrical nerve stimulation (TENS) influence hypoalgesia? A systematic review of studies using experimantal pain and healthy human participants, Physiotherapy, 2008, vol. 94: 11-20.
Claydon LS et al., Dose-specific effects of transcutaneous electrical nerve stimulation on experimental pain, Clinical Journal of Pain, 2011, vol. 27(7): 635-647.
Cole, R.J. et al., Automatic Sleep/Wake Identification From Wrist Activity, Sleep, 1992, 15(5), p. 461-469.
Cruccu G. et al., EFNS guidelines on neurostimulation therapy for neuropathic pain, European Journal of Neurology, 2007, vol. 14: 952-970.
Dailey, D. et al., Transcutaneous Electrical Nerve Stimulation Reduces Movement-Evoked Pain and Fatigue: A Randomized, Controlled Trial, Arthritis & Rheumatology, May 2020, vol. 72, No. 5, pp. 824-836.
Davies HTO et al., Diminishing returns or appropriate treatment strategy?—an analysis of short-term outcomes after pain clinic treatment, Pain, 1997, vol. 70: 203-208.
Desantana JM et al., Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain, Curr Rheumatol Rep. 2008, vol. 10(6): 492-499.
Dubinsky RM et al., Assessment: Efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurology, Neurology, 2010, vol. 74: 173-176.
Fary RE et al., Monophasic electrical stimulation produces high rates of adverse skin reactions in healthy subjects, Physiotherapy Theory and Practice, 2011, vol. 27(3): 246-251.
Fishbain, David A. et al. Does Pain Mediate the Pain Interference with Sleep Problem in Chronic Pain? Findings from Studies for Management of Diabetic Peripheral Neuropathic Pain with Duloxetine, Journal of Pain Symptom Management, Dec. 2008; 36(6):639-647.
Fishbain, David A. et al., Transcutaneous Electrical Nerve Stimulation (TENS)Treatment Outcome in Long-Term Users, The Clinical Journal of Pain, Sep. 1996; 12(3):201-214.
Food and Drug Administration, Draft Guidance for Industry and Staff: Class II Special Controls Guidance Document: Transcutaneous Electrical Nerve Stimulator for Pain Relief, Apr. 5, 2010.
Garrison DW et al., Decreased activity of spontaneous and noxiously evoked dorsal horn cells during transcutaneous electrical nerve stimulation (TENS), Pain, 1994, vol. 58: 309-315.
Gilron, I. et al., Chronobiological Characteristics of Neuropathic Pain: Clinical Predictors of Diurnal Pain Rhythmicity, The Clinical Journal Of Pain, 2013.
Gozani SN et al., Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation for Treatment of Chronic Low Back and Lower Extremity Pain, Journal of Pain Research, 2016, vol. 9, pp. 469-479.
Hausdorff, J.M. et al., Gait Variability and Fall Riskin Community-Living Older Adults: A 1-Year Prospective Study, Arch Phys Med Rehabil, Aug. 2001, vol. 82, pp. 1050-1056.
Hori, T. et al., Skin Potential Activities And Their Regional Differences During Normal Sleep In Humans, The Japanese Journal of Physiology, 1970, vol. 20, p. 657-671.
Jelinek HF et al., Electric pulse frequency and magnitude of perceived sensation during electrocutaneous forearm stimulation, Arch Phys Med Rehabil, 2010, vol. 91: 1372-1382.
Jin DM et al., Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials, Diabetes Research and Clinical Practice, 2010, vol. 89: 10-15.
Johnson MI et al., Analgesic effects of different frequencies of transcutaneous electrical nerve stimulation on cold-induced pain in normal subjects, Pain, 1989, vol. 39: 231-236.
Johnson MI et al., Transcutaneous Electrical Nerve Stimulation (TENS) and TENS-like devices: do they provide pain relief?, Pain Reviews, 2001, vol. 8: 7-44.
Johnson MI et al., Transcutaneous electrical nerve stimulation forthe management of painful conditions: focus on neuropathic pain, Expert Review of Neurotherapeutics, 2011, vol. 11(5): 735-753.
Johnson, M.I. et al., An in-depth study of long-term users of transcutaneous electrical nerve stimulation (TENS). Implications for clinical use of TENS. Pain. Mar. 1991;44(3):221-229.
Kaczmarek, Kurt A. et al.. Electrotactile and Vibrotactile Displays for Sensory Substitution Systems. IEEE Trans. Biomed. Eng. Jan. 1991;38 (1):1-16.
Kantor G et al., The effects of selected stimulus waveforms on pulse and phase characteristics at sensory and motor thresholds, Physical Therapy, 1994, vol. 74(10): 951-962.
Keller, Thierry et al., Electrodes for transcutaneous (surface) electrical stimulation. J. Automatic Control, University of Belgrade. 2008; 18(2):35-45.
Koumans, A. J. R. et al., Electrodermal Levels And Fluctuations During Normal Sleep, Psychophysiology, 1968, 5(3), p. 300-306.
Kovacevic-Ristanovic, R. et al., Nonpharmacologic Treatment of Periodic Leg Movements in Sleep, Arch. Phys. Med. Rehabil., 1991, vol. 72, p. 385-389.
Kripke, D.F. et al., Wrist Actigraphic Scoring for Sleep Laboratory Patients: Algorithm Development, Journal of Sleep Research, 2010, 19(4), p. 612-619.
Law PPW et al., Optimal stimulation frequency of transcutaneous electrical nerve stimulation on people with knee osteoarthritis, J Rehabil Med, 2004, vol. 36: 220-225.
Leonard G et al., Deciphering the role of endogenous opioids in high-frequency TENS using low and high doses of naloxone, Pain, 2010, vol. 151: 215-219.
Levy et al., A comparison of two methods for measuring thermal thresholds in diabetic neuropathy, Journal of Neurology, Neurosurgery, and Psychiatry, 1989, vol. 52: 1072-1077.
Lopes, L. et al., Restless Legs Syndrome and Quality of Sleep in Type 2 Diabetes, Diabetes Care, 2005, vol. 28, No. 11, p. 2633-2636.
Lykken, D.T., Properties of Electrodes Used in Electrodermal Measurement. J. Comp. Physiol. Psychol. Oct. 1959; 52:629-634.
Lykken, D.T., Square-Wave Analysis of Skin Impedance. Psychophysiology. Sep. 1970; 7(2):262-275.
Macfarlane, T. et al., Whether the weather influences pain? Results from EpiFunD study in North West England, Rheumatology, 2010, vol. 49, pp. 1513-1520.
Melzack R et al., Pain mechanisms: A New Theory, Science, 1965, vol. 150(3699): 971-979.
Moran F et al., Hypoalgesia in response to transcutaneous electrical nerve stimulation (TENS) depends on stimulation intensity, The Journal of Pain, 2011, vol. 12(8): 929-935.
Nightingale, S., The neuropathic pain market, Nature Reviews, 2012, vol. 11, p. 101-102.
Okamoto-Mizuno. K. et al., Effects of thermal environment on sleep and circadian rhythm, Journal of Physiological Anthropology, 2012, vol. 31, No. 14, pp. 1-9.
Oosterhof, Jan et al., Outcome of transcutaneous electrical nerve stimulation in chronic pain: short-term results of a double-blind, randomised, placebo-controlled trial. J. Headache Pain. Sep. 2006; 7 (4):196-205.
Oosterhof, Jan et al., The long-term outcome of transcutaneous electrical nerve stimulation in the treatmentfor patients with chronic pain: a randomized, placebo-controlled trial. Pain Pract. Sep. 2012; 12(7):513-522.
Ossipov MH et al., Central Modulation of Pain, The Journal of Clinical Investigation, Nov. 2010, vol. 120, No. 11, pp. 3779-3787.
Pantaleao MA et al., Adjusting pulse amplitude during transcutaneous electrical nerve stimulation (TENS) application produces greater hypoalgesia, The Journal of Pain, 2011, vol. 12(5): 581-590.
Paquet, J. et al., Wake Detection Capacity of Actigraphy During Sleep, Sleep, 2007, 30(10), p. 1362-1369.
Pieber K et al., Electrotherapy forthe treatment of painful diabetic peripheral neuropathy: a review, Journal of Rehabilitation Medicine, 2010, vol. 42: 289-295.
Raskin, J. et al., A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of Diabetic Peripheral Neuropathic Pain, Pain Medicine, 2005, 6(5), p. 346-356.
Sadeh, A., The Role and Validity of Actigraphy in Sleep Medicine: An Update, Sleep Medicine Reviews, 2011, vol. 15, p. 259-267.
Sadosky, A. et al., Burden of Illness Associated with Painful Diabetic Peripheral Neuropathy Among Adults Seeking Treatment in the US: Results from a Retrospective Chart Reviewand Cross-Sectional Survey, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, vol. 6, p. 79-92.
Sano, A et al., Quantitative analysis of wrist electrodermal activity during sleep, International Journal of Psychophysiology, 2014, vol. 94, pp. 382-389.
Scherder, E. J. A. et al., Transcutaneous Electrical Nerve Stimulation (TENS) Improves the Rest-Activity Rhythm in Midstage Alzheimer's Disease, Behavioral Brain Research, 1999, vol. 101, p. 105-107.
Sheridan et al., Some Factors Influencing the Threshold of the Electrocutaneous Stimulus, Perceptual and Motor Skills, 1966, vol. 22, pp. 647-654.
Susi et al., Motion Mode Recognition and Step Detection Algorithms for Mobile Phone Users, Sensors, Jan. 24, 2013, vol. 13, pp. 1539-1562.
Timmermans, E. et al., Self-perceived weather sensitivity and joint pain in older people with osteoarthritis in six European countries: results from the European Project on OSteoArthritis (EPOSA), BMC Musculoskeletal Disorders, 2014, vol. 15, No. 66, pp. 1-11.
Tryon, W. W., Issues of Validity in Actigraphic Sleep Assessment, Sleep, 2004, 27(1), p. 158-165.
Tsai, Y. et al., Impact of Subjective Sleep Quality on Glycemic Control in Type 2 Diabetes Mellitus, Family Practice, 2012, vol. 29, p. 30-35.
Van Boxtel, A., Skin resistance during square-wave electrical pulses of 1 to 10 mA. Med. Biol. Eng. Comput. Nov. 1977; 15(6):679-687.
Van Someren, E. J. W. et al., Gravitational Artefact in Frequency Spectra of Movement Acceleration: Implications for Actigraphy in Young and Elderly Subjects, Journal of Neuroscience Methods, 1996, vol. 65, p. 55-62.
Waeber, R. et al., Biosection Search with Noisy Responses, SIAM J. Control Optim., 2013, vol. 51, No. 3, pp. 2261-2279.
Webster, J. B. et al., An Activity-Based Sleep Monitor System for Ambulatory Use, Sleep, 1982, 5(4), p. 389-399.
Zelman, D. C. et al., Sleep Impairment in Patients With Painful Diabetic Peripheral Neuropathy, The Clinical Journal Of Pain, 2006, 22(8), p. 681-685.
Zucconi, M. et al., The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG), Sleep Medicine, 2006, vol. 7, p. 175-183.
Dailey DL et al., Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain, Fatigue, and Hyperalgesia while Restoring Central Inhibition in Primary Fibromyalgia, Pain, Nov. 2013, vol. 154, No. 11, pp. 2554-2562.
Related Publications (1)
Number Date Country
20210205607 A1 Jul 2021 US
Provisional Applications (2)
Number Date Country
61657382 Jun 2012 US
61560029 Nov 2011 US
Continuations (3)
Number Date Country
Parent 16175212 Oct 2018 US
Child 17122439 US
Parent 15350261 Nov 2016 US
Child 16175212 US
Parent 13678221 Nov 2012 US
Child 14610757 US
Continuation in Parts (1)
Number Date Country
Parent 14610757 Jan 2015 US
Child 15350261 US